Ondine Announces Periowave(TM) Photodisinfection Data Published in The Journal of Clinical Dentistry(R)

    VANCOUVER, April 2 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) today announced the publication of a peer-reviewed research paper in
the April 2007 issue of Journal of Clinical Dentistry entitled, "Treatment of
Periodontal Disease by Photodisinfection Compared to Scaling and Root
Planing". In this randomized and controlled study, the authors reported that
the Periowave(TM) photodisinfection system improved the clinical attachment
level by 239% at 12 weeks over the standard approach of scaling and root
planing alone (p=0.02). The study was conducted by clinicians at a group
practice located in Everett, Washington.
    The objective of the Everett trial was to examine the efficacy and safety
of Periowave(TM) in patients with moderate to severe adult periodontitis. The
trial included 33 patients between the ages of 18-75 years of age in a
suburban Seattle/Everett population. There were a total of 622 treatment sites
that were treated and followed for 12 weeks. The primary outcome of the trial
was to assess the difference between patients treated with Periowave(TM) plus
scaling and root planing to those treated with scaling and root planing alone.
    In addition to the statistically significant improvement in clinical
attachment level, in 33% of treated subjects, Periowave(TM) therapy resulted
in average pocket depth reductions exceeding 1.5 mm. None of the subjects in
the scaling and root planing alone group experienced recoveries of this
    "The data presented in this paper further validates our belief that
Periowave(TM) will become part of the standard of care for the treatment of
periodontal disease", said Carolyn Cross, President and CEO of Ondine
Biopharma. "We will continue to evaluate Periowave(TM) under different
conditions of clinical use, for extended follow-up periods and for other oral
infections and applications."

    About Periowave(TM) and Photodisinfection (PDD)

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and one
or more lasers are used to activate the compounds and complete the
disinfection. The Photodisinfection technologies were developed by Professor
Michael Wilson and colleagues at the Eastman Dental Institute, University
College London, and licensed to Ondine by UCL Business PLC, University College
London. Additional information about Periowave(TM) is available at

    About Ondine Biopharma Corporation:

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance.
    The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Redmond, Washington, USA, a sales and marketing
subsidiary in York, Pennsylvania, and an international office in St Michael,
Barbados. For additional information, please visit the Company's website at:

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890